PUNE, India, July 18, 2024 /PRNewswire/ -- Within the
pharmaceutical sector, a specialized organization known as a
Contract Development and Manufacturing Organization (CDMO) for
Active Pharmaceutical Ingredients (APIs) offers a wide range of
services that involve the development and production of APIs. The
complexity of active pharmaceutical ingredients (APIs) is
increasing, small molecules are becoming more common, and
cost-cutting measures are driving the rapid increase of outsourcing
services in the pharmaceutical industry.
Maximize Market Research, a Healthcare business research firm
has published a report on the Global Active Pharmaceutical
Ingredients CDMO Market. The total market size for the Active
Pharmaceutical Ingredients CDMO Market was USD 118.2 Bn in 2023 and is expected to grow at
7.06 percent CAGR through the forecast period by reaching nearly
USD 19.11 Bn by 2030.
The Active Pharmaceutical Ingredients CDMO Market research
provides in-depth details on important variables such as motivating
factors and obstacles that are expected to determine the market's
future growth. Along with a thorough analysis of the competitive
landscape, the report also includes available opportunities for
stakeholders to invest in the Active Pharmaceutical Ingredients
CDMO Market. Both qualitative and quantitative characteristics of
the industry have also been covered in the report. The scope of the
MMR report includes a thorough analysis of regional markets for the
Active Pharmaceutical Ingredients CDMO Market. The data from
primary and secondary sources are combined to create a report that
provides information on the conditions required for higher
growth.
Get your Sample PDF:
https://www.maximizemarketresearch.com/request-sample/122726/
Market Size in
2023
|
USD 118.2Bn
|
Market Size in
2030
|
USD 190.11
Bn
|
CAGR
|
7.06 Percent
|
Forecast
Period
|
2024-2030
|
Base
Year
|
2023
|
Number of
Pages
|
229
|
No. of
Tables
|
138
|
No. of Charts and
Figures
|
193
|
Segment
Covered
|
By Product Type, Drug,
Synthesis, Workflow, and Application
|
Regional
Scope
|
North America, Europe,
Asia Pacific, Middle East and Africa, South America
|
Report
Coverage
|
Market Share, Size, and
Forecast by Revenue | 2024−2030, Market Dynamics, Growth Drivers,
Restraints, Investment Opportunities, and Key Trends, Competitive
Landscape, Key Players Benchmarking, Competitive Analysis, MMR
Competition Matrix, Competitive Leadership Mapping, Global Key
Players' Market Ranking Analysis.
|
Highlights of the Report
- CDMOs are playing an increasingly important role in the
pharmaceutical industry, as they offer a cost-effective way for
pharmaceutical companies to develop and manufacture APIs.
- The demand for complex APIs, such as highly potent APIs
(HP-APIs) and Antibody-Drug Conjugates (ADCs), is driving the
growth of the CDMO market.
- The US is expected to maintain its leadership position in terms
of innovation and high-value API CDMO services.
Increasing Demand for Oncology APIs to Drive Growth
The demand for cancer-active pharmaceutical ingredients (APIs)
is being driven by the rising number of cancer patients globally,
which presents a big potential for Contract Development and
Manufacturing Organizations (CDMOs). According to MMR analysis,
globally there have been about 10 million cancer deaths and 20
million new cases in 2022, with estimates indicating that number
will increase to 35 million cases by 2050. The need for customized
APIs is rising as a result of this growth, and major pharmaceutical
companies are depending more on CDMOs for their affordable
manufacturing. Pharmaceutical firms benefit from measures provided
by CDMOs, such as reduced manufacturing costs and improved
production procedures. For instance, using CDMOs for outsourcing
leads to a 30% reduction in manufacturing costs. Cancer APIs are
now in a growth phase of their industrial life cycle, which is
marked by intense competition and a high level of market
concentration. Key Players in the CDMO, such as Lonza, Catalent,
and Samsung Biologics, control the majority of the market share. A
consistent supply of quality cancer APIs that satisfy strict
regulatory criteria is guaranteed by their advanced production
capabilities and significant investments in cutting-edge
technology. Additionally, trade policy influences business profits
and the whole economy, which makes international import-export a
significant factor in the cancer API industry. For instance,
the United States and the European
Union's positive financial relations have made effortless
international trade possible, increasing the availability of cancer
APIs and helping in the worldwide battle against cancer.
For more details on the information, Request a sample
report.
https://www.maximizemarketresearch.com/request-sample/122726/
Asia Pacific Active Pharmaceutical Ingredients CDMO Market to
be Largest
The Asia Pacific Active Pharmaceutical Ingredients (API)
Contract Development and Manufacturing Organization (CDMO) market
is characterized by a lower cost of manufacturing compared to other
parts of the world. The reason behind this cost advantage is the
much-reduced labor expenses in countries like China and India, where typical salaries in the
pharmaceutical manufacturing industry are lower than those in the
US and Europe. Companies in the
Asia-Pacific region develop APIs
for barely, thanks to the difference in labor expenses. The
Asia Pacific region offers cost
advantages as well as a strong supply chain network. Under the vast
networks of raw material suppliers that China and India have established, lead times and
production costs are lowered. For example, China supplies more than 68% of India's bulk medication demand, guaranteeing a
reliable and affordable raw material supply. The region also boasts
a highly skilled workforce with a growing number of trained
professionals in pharmaceutical sciences and chemical engineering.
Educational institutions in India
and China are producing over
300,000 graduates annually in relevant fields, ensuring a steady
inflow of skilled labor into the industry. This skilled workforce
is crucial for maintaining high-quality standards and innovation in
API production. With subsidies, tax credits, and faster regulatory
approvals, the Chinese government's "Made in China 2025" program and India's "Pharma Vision 2020" have established
a favorable atmosphere for the production of pharmaceuticals.
For a detailed analysis of regions and their
contributions
Request For Free Sample Report:
https://www.maximizemarketresearch.com/request-sample/122726/
Key Player Offerings
- To meet the growing demand for CDMO Services, Lonza has built a
bigger facility to make bioconjugates in Visp, Switzerland. This allows Lonza to work with
more companies, including those just starting to develop new
drugs.
- Siegfried, a company that manufactures active ingredients for
medicines acquired Grafton,
Wisconsin (US) intending to develop a Siegfried Acceleration
Hub for early-phase CDMO services to provide comprehensive support
to customers in the pre-clinical and clinical development and
manufacturing of Drug Substances.
Active Pharmaceutical Ingredients CDMO Market
Segmentation
By Product
Type
- Traditional Active Pharmaceutical Ingredient (Traditional
API)
- Highly Potent Active Pharmaceutical Ingredient (HP-API)
- Antibody-Drug Conjugate (ADC)
- Other
By Application
- Oncology
- Hormonal
- Glaucoma
- Cardiovascular
- Diabetes
- Other
Active Pharmaceutical Ingredients CDMO Market Key
Players
- 10x Genomics
- Cambrex
- Recipharm
- Thermo Fisher Pantheon
- Corden Pharma
- Samsung Biologics
- Lonza
- Others
Key questions answered in the Active Pharmaceutical
Ingredients CDMO Market are:
- What is Active Pharmaceutical Ingredients CDMO?
- What is the current growth rate of the Active Pharmaceutical
Ingredients CDMO market?
- Who are the key players in the Active Pharmaceutical
Ingredients CDMO Market?
- What are the factors affecting growth in the Active
Pharmaceutical Ingredients CDMO Market?
- Who held the largest market share in the Active Pharmaceutical
Ingredients CDMO Market?
- What is the demand pattern for the Active Pharmaceutical
Ingredients CDMO Market?
- What are the key trends in the Active Pharmaceutical
Ingredients CDMO Market?
- What are the growth prospects in developing countries for the
Active Pharmaceutical Ingredients CDMO Market?
- Which segment is expected to witness the fastest growth and why
in the Active Pharmaceutical Ingredients CDMO Market?
Key Offerings:
- Past Market Size and Competitive Landscape (2018 to 2022)
- Past Pricing and price curve by region (2018 to 2022)
- Market Size, Share, Size & Forecast by Different Segment |
2024−2030
- Market Dynamics – Growth Drivers, Restraints, Opportunities,
and Key Trends by Region
- Market Segmentation – A detailed analysis by Product Type,
Drug, Synthesis, Workflow, Application, and Region.
- Competitive Landscape – Profiles of selected key players by
region in a strategic perspective
- Competitive landscape – Market Leaders, Market Followers,
Regional player
- Competitive benchmarking of key players by region
- PESTLE Analysis
- PORTER's analysis
- Value chain and supply chain analysis
- Legal Aspects of business by region
- Lucrative business opportunities with SWOT analysis
- Recommendations
Maximize Market Research is leading Healthcare research firm,
has also published the following reports:
Nuclear Medicine/Radiopharmaceuticals Market: The
market size in 2023 was worth US $ 6.04
Bn at a CAGR of 9 % and it is expected to reach US
$ 11.05 Bn in 2030.
Pharmaceutical Logistics Market: The market size
was valued at USD 88.89 Bn. in 2022
and the total Pharmaceutical Logistics revenue is expected to grow
at a CAGR of 9.2% from 2023 to 2029, reaching nearly USD 164.61 Bn.
Antibody Drug Conjugates Market: The market size
was valued at USD 9.8 Billion in 2023
and the total Antibody Drug Conjugates revenue is expected to grow
at a CAGR of 15.4% from 2024 to 2030, reaching nearly USD 22.5 Billion by 2030.
ADC Technology Market: The market size was
valued at USD 7.60 Bn in 2022 and is
expected to reach USD 14.44 Bn by
2029, at a CAGR of 9.6 %.
US over the Counter Pharmaceuticals Market: The
market size was valued at USD 42.50
Billion in 2023 and the total US over the Counter
Pharmaceuticals revenue is expected to grow at a CAGR of 5.6% from
2023 to 2030, reaching nearly USD 62.24
Billion in 2030.
About Maximize Market Research:
Maximize Market Research is a multifaceted market
research and consulting company with professionals from several
industries. Some of the industries we cover include medical
devices, pharmaceutical manufacturers, science and engineering,
electronic components, industrial equipment, technology and
communication, cars and automobiles, chemical products and
substances, general merchandise, beverages, personal care, and
automated systems. We provide market-verified industry estimations,
technical trend analysis, crucial market research, strategic
advice, competition analysis, production and demand analysis, and
client impact studies.
Contact Maximize Market Research:
3rd Floor, Navale IT
Park, Phase 2
Pune Banglore Highway, Narhe,
Pune, Maharashtra 411041,
India
sales@maximizemarketresearch.com
+91 9607365656
Follow Up: Facebook | Twitter
| LinkedIn | Instagram
Logo:
https://mma.prnewswire.com/media/2457992/Maximize_Market_Research_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/active-pharmaceutical-ingredients-cdmo-market-to-be-dominated-by-oncology-segment-to-reach-190-11-bn-by-2030---says-maximize-market-research-302200484.html